Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Only a small subset of extracted claims are supported by the provided label excerpts (notably topical application to the affected area and pruritus/itching as a local adverse reaction). Many indication- and counseling-related statements are not supported by the supplied label sections, including MRSA/decolonization-related claims.
Category Scores
Accurate Statements
Mupirocin is applied directly to the affected skin area.
DOSAGE AND ADMINISTRATION: “should be applied to the affected area”
Common local effects of mupirocin include itching.
ADVERSE REACTIONS: “pruritus” (each in 1% of patients)
Unsupported Statements
Mupirocin ointment is used for infected cuts.
Not supported by the provided INDICATIONS AND USAGE excerpt (indication stated as impetigo due to S. aureus and S. pyogenes only).
Mupirocin ointment is used for abrasions.
Not supported by the provided INDICATIONS AND USAGE excerpt.
Mupirocin ointment is used for superficial skin lesions when bacteria are the suspected cause.
Not supported by the provided INDICATIONS AND USAGE excerpt.
Mupirocin is prescribed for localized skin infections that may be caused by susceptible bacteria.
Not supported by the provided INDICATIONS AND USAGE excerpt, which specifies impetigo due to S. aureus and S. pyogenes.
Mupirocin is not used for viral skin conditions such as cold sores.
No such limitation is present in the provided label excerpts.
Mupirocin is not used for most fungal rashes unless there is a specific reason to target bacteria as well.
No such limitation is present in the provided label excerpts.
Mupirocin works by stopping bacterial growth.
Mechanism-of-action statement is not present in the provided label excerpts (CLINICAL PHARMACOLOGY excerpt provided does not describe this).
Patients typically apply a thin layer of mupirocin to the infected area.
No “thin layer” instruction is present in the provided DOSAGE AND ADMINISTRATION excerpt (only “a small amount” is stated).
Mupirocin should be used exactly as directed on the prescription label or by a clinician.
No such general directive is present in the provided label excerpts.
Common local effects of mupirocin include redness.
Not listed in the provided ADVERSE REACTIONS excerpt.
Common local effects of mupirocin include burning.
Not listed in the provided ADVERSE REACTIONS excerpt.
Common local effects of mupirocin include irritation.
Not listed in the provided ADVERSE REACTIONS excerpt.
Patients should seek medical advice if symptoms worsen quickly or spread while using mupirocin.
No such patient counseling/monitoring instruction is present in the provided label excerpts.
Patients should seek medical advice if there are signs of an allergic reaction to mupirocin, such as significant swelling or hives.
No allergic-reaction counseling instruction is present in the provided label excerpts.
Mupirocin is sometimes used in settings where MRSA is a concern.
MRSA-related use is not supported by the provided INDICATIONS AND USAGE excerpt.
Mupirocin is used to treat localized infections in certain settings where MRSA is a concern.
MRSA-related use is not supported by the provided INDICATIONS AND USAGE excerpt.
Mupirocin is used as part of decolonization approaches in certain patient groups.
Decolonization-related use is not supported by the provided INDICATIONS AND USAGE excerpt.
Overuse or using mupirocin for the wrong condition can contribute to antibiotic resistance.
No antibiotic-resistance/stewardship rationale is present in the provided label excerpts.
Using mupirocin only for the specific skin infection it was prescribed for helps reduce the risk of antibiotic resistance.
No antibiotic-resistance/stewardship rationale is present in the provided label excerpts.
Contradictions
Important Omissions
The provided label excerpt specifies indication limited to topical treatment of impetigo due to Staphylococcus aureus and Streptococcus pyogenes; the extracted claims do not reflect this specificity in several places.
Importance:
Moderate
The provided label excerpt includes a re-evaluation timeframe if no clinical response within 3 to 5 days; extracted claims do not include this requirement.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims broaden indication beyond the provided label (impetigo due to specific organisms) and include MRSA/decolonization, which are not supported by the supplied label excerpts; missing label-specific re-evaluation guidance also reduces accuracy for safe use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Major portions of extracted claims are not supported by the provided FDA label excerpts, especially indication overreach (cuts/abrasions/lesions), MRSA/decolonization use, and patient counseling and mechanism statements.
Suggested Improvement
Restrict claims to the provided label indication (impetigo due to S. aureus and S. pyogenes) and to label-supported administration guidance (small amount applied to affected area three times daily; re-evaluate if no response within 3 to 5 days). Remove or qualify unsupported MRSA/decolonization, viral/fungal exclusions, mechanism wording, and unsourced counseling statements.